Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Titel:
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Auteur:
Javle, Milind Roychowdhury, Sameek Kelley, Robin Kate Sadeghi, Saeed Macarulla, Teresa Weiss, Karl Heinz Waldschmidt, Dirk-Thomas Goyal, Lipika Borbath, Ivan El-Khoueiry, Anthony Borad, Mitesh J Yong, Wei Peng Philip, Philip A Bitzer, Michael Tanasanvimon, Surbpong Li, Ai Pande, Amit Soifer, Harris S Shepherd, Stacie Peacock Moran, Susan Zhu, Andrew X Bekaii-Saab, Tanios S Abou-Alfa, Ghassan K